IRVINE, Calif., Oct. 19, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Transcatheter tricuspid valve replacement using the ...

Edwards (NYSE:EW) said that it has received FDA approval for its Evoque tricuspid valve replacement system for the treatment of tricuspid regurgitation. The medical device maker said the system is the ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the first transcatheter tricuspid valve replacement system. The system is indicated for ...

The Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after implant, according to an update from the TRISCEND II trial. Among study ...

The investigational transfemoral EVOQUE tricuspid valve replacement system (Edwards Lifesciences) significantly reduced severity of tricuspid regurgitation and improved quality of life at 30 days in ...

UC San Francisco interventional cardiologists and interventional echocardiographers recently performed the health system’s first commercial transcatheter tricuspid valve replacement procedure using ...

While minimally invasive repair devices have shown progress in stemming leaks of the heart’s notoriously tricky tricuspid valve, Edwards Lifesciences aims to show that replacing the valve entirely ...